Cell line · CVCL_D627
Papers52
1 to 20 of 52
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9-CD36 Axis in Obesity-Associated Pancreatic Adenocarcinoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cblb Gene Editing in T Cells Sustains Expansion and Immunogenic CAR T Tumor Killing Under Chronic Antigenic Stimulation. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| WT1-Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. | Mol Ther Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting plasticity in the pyrimidine synthesis pathway potentiates macrophage-mediated phagocytosis in pancreatic cancer models. | J Clin Invest | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD63-Mediated SARS-CoV-2 RBD Fusion Neoantigen DNA Vaccine Enhances Antitumor Immune Response in a Mouse Panc02 Model via EV-Targeted Delivery. | Vaccines (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| RACK1 attenuates pancreatic tumorigenesis by suppressing acinar-to-ductal metaplasia through inflammatory signaling modulation. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dual asparagine-depriving nanoparticles against solid tumors. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_D627/papers